Medical Devices Today

Neurovascular Market's Time Has Come: Stealthy Sequent Medical Unveils Strategy

Article preview from Start-Up - September 1, 2011

With foresight, good timing, or simply years of experience, the founders of Sequent Medical (who also founded MicroVention) are launching a new endovascular product in Europe just as large companies are signalling their interest in the space via acquisitions. For the treatment of cerebral aneurysms, Sequent has developed a novel device that combines the best attributes of embolization coils and flow diverters, its founders believe.

Device IPO Class of 2007 Making News, Some Returns

Article preview from Start-Up - March 01, 2011

The merger of Accuray and TomoTherapy would combine two of the 11 medical device companies that went public in 2007, a class of companies that has produced mixed results.

Hologic Buys Interlace Medical, Acquires Missing Link In Gynecology Surgery

Article preview from IN VIVO - January, 2011

Gynecologists generally have the opportunity to perform in-office procedures for three indications: abnormal uterine bleeding, permanent contraception and uterine fibroids. Hologic had supplied its 460 medical device reps in the US - the largest force in women's health - with the tools to perform two of these procedures, but couldn't offer the third piece of the puzzle, an in-office treatment for fibroids, a gap which, until now, hasn't been filled by any product on the market. Hologic is filling in the missing piece with the acquisition of privately held Interlace Medical, a start-up developing MyoSure, a minimally invasive resection device for submucosal fibroids.

J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General

Article preview from In-Vivo- January 1, 2011

Mass General has signed a $30 million deal with two units of J&J to develop a new system for capturing and analyzing circulating tumor cells (CTCs). The collaboration aims to develop a standardized diagnostic platform for biomarker analysis of DNA, RNA, or protein from tumor cells collected noninvasively. J&J will take the indications for its current CTC system, CellSearch, and migrate them to the new platform.

Deals in Depth: June/July 2010

Article preview from In-Vivo - September, 2010

Front-runners for June alliances were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million. Leading the pack for biopharma M&A was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris. In financings, both biopharma and device companies were busy raising private money, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).

Medtronic Looks to Strengthen Spine with Osteotech Purchase

Article preview from In-Vivo - September, 2010

Medtronic, struggling to hold onto its sizable share of the shrinking spinal market, made a bid for publicly traded Osteotech, a maker of a demineralized bone matrix agent that will broaden the company's regenerative product portfolio.

Deals in Depth: July 2010

Article preview from In-Vivo - July, 2010

Alliance leaders included GSK's €73.9 million investment in new partner Dong-A Pharmaceutical and Medtronic's $70 million investment in cardiovascular device company BioControl. Abbott led biopharma M&A activity with its $3.7 billion purchase of Piramal's healthcare solutions business. In devices, Endo paid $221 million up front for HealthTronics. Roughly 30 percent of the month's $953 million in biopharma fundraising came from Salix's $291 million debt deal. No public device dollars were realized in May, though 11 companies completed venture rounds.

The Future of Laparoscopy: Single Incision, NOTES and Robots

Article preview from Start Up - July, 2010

The skill sets of laparoscopy, endoscopy, robotics and even interventional cardiology are all converging to create least invasive surgeries that take laparoscopy as a point of departure but change how surgeons access the abdominal cavity. Start-ups are innovating to supply the new surgical instruments.

Medtronic buys Invatec for $350mm, plus earn-outs

Deal summary reprinted from Strategic Transactions - January, 2010

Medtronic has agreed to acquire closely held European interventional cardio device developer Invatec and its affiliates Fogazzi (provides Invatec with polymer technology) and Krauth Cardiovascular (Invatec's German distributor) for $350mm. It will also provide earn-outs of up to $150mm if certain milestones are reached.

Medtronic to Acquire Invatec For $350 Million

Acquisition Will Expand Product Offering and Pipeline for Cardiovascular Interventions

Press release reprinted from www.medtronic.com

Editor's Note: Invatec was featured in the October 2009 issue of IN VIVO. Purchase "Invatec: Translating Global Success in Vascular Devices to the US Market" to learn more about Invatec's track record, management team and strategic vision for the U.S. vascular device and interventional cradiology markets.

MINNEAPOLIS – Jan. 25, 2010 – Moving to expand its impact on peripheral vascular disease, Medtronic, Inc. (NYSE: MDT), announced today that it has signed a definitive agreement to acquire Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease, and two affiliated companies: Fogazzi, which provides polymer technology to Invatec; and Krauth Cardiovascular, which distributes Invatec products in Germany. The agreement calls for Medtronic to make an initial payment of $350 million to Invatec and additional payments of up to $150 million for Invatec’s achievement of specific milestones.